| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (NCT04759911) | M.D. Anderson Cancer Center | 2021-02-26 |
| Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers (NCT03892993) | M.D. Anderson Cancer Center | 2019-04-09 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (NCT02592356) | M.D. Anderson Cancer Center | 2015-11-16 |
| Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer (NCT02293954) | City of Hope Medical Center | 2015-11-11 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (NCT01709435) | National Cancer Institute (NCI) | 2012-11-14 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (NCT01204476) | National Cancer Institute (NCI) | 2010-10-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer (NCT00519896) | University of Washington | 2007-07-01 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer (NCT00134043) | National Cancer Institute (NCI) | 2005-12-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (NCT00118248) | National Cancer Institute (NCI) | 2004-12-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |